Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
AssigneePacific Arrow Limited
InventorsPui-Kwong CHAN, May Sung MAK, Yun WANG
Life of this patent
Estimating the term…
Loading patent…
AssigneePacific Arrow Limited
InventorsPui-Kwong CHAN, May Sung MAK, Yun WANG
Estimating the term…
This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder. This invention provides compounds comprising at least one sugar, a triterpene, such as Sapogenin, and at least one side chains at Carbon 21 and 22, such as Angeloyl groups. The compounds of the present have various pharmaceutical and therapeutic applications.
1-223. (canceled)
A method for inhibiting cancer cell growth, comprising contacting the cells with an effective amount of saponins extract from Wenguanguo or Xanthoceras Sorbifolia, wherein the cancer is selected from the group consisting of breast cancer, leukocyte cancer, liver cancer, ovary cancer, bladder cancer, prostate cancer, bone cancer, colon cancer, cervix cancer, lung cancer and brain cancer, wherein the saponins effective drug concentration is 40-1 05 ug/ml for breast cancer, 25-50 ug/ml for leukocyte cancer, 35-55 ug/ml for bladder cancer, 10-20 ug/ml for ovarian cancer, 50-100 ug/ml for brain cancer, 20-70 ug/ml for prostate cancer, 90-1 30 ug/ml for lung cancer, 50-90 ug/ml for liver cancer, and 90-1 60 ug/ml for cervix cancer.
Dependencies are inferred from the claim text.